Strategies to Improve Outcomes in Patients with Asthma
This CME Program will provide physicians with imperative information about the rationale of asthma control for each stage of disease. Expert panel will discuss biomarkers of disease activity, new biologics and the asthma and COPD overlap syndrome among other relevant topics. Physicians will also be exposed to different disease monitoring tools as well as recent clinical trial data to ensure appropriate and individualized treatment plans can be implemented in their practice. With the information provided, learners will be able to better treat and manage their asthma patients and improve overall quality of life in those individuals through both short-term gains and long-term successes.
Target Audience
Allergists/Immunologists, pulmonologists, primary care physicians, and other healthcare clinicians responsible for the care of patients with asthma
Educational Objectives
Upon completion of this activity, participants will be able to:
- Examine the pathology of asthma, and discuss the characteristics of pediatric and adult-onset asthma to ensure differential diagnosis
- Review the rationale of asthma control of each stage of disease, in addition to disease monitoring tools and recent clinical trial data to ensure appropriate treatment selection
- Implement patient education and communication tactics in individualized treatment plans to improve patient adherence, self-management, and overall quality of life in asthma patients
Faculty
Reynold A. Panettieri, Jr, MD | |
Bradley Chipps, MD | |
![]() |
Jonathan Corren, MD |
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Faculty | Relationship Identified With: |
Reynold A. Panettieri, Jr, MD | Consultant/Advisor: AstraZeneca; Johnson and Johnson Research Institute for Fragrance Materials; Teva Pharmaceuticals Industries Ltd. Grant/Research Support: AstraZeneca; Gilead Sciences, Inc.; Johnson and Johnson; Merck & Co., Inc.; Research Institute for Fragrance Materials; Roche; Sanofi-aventis U.S. LLC |
Bradley Chipps, MD | Consultant/Advisor: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; Meda Pharmaceuticals Inc.; Merck & Co., Inc; Novartis Speaker's Bureau: AstraZeneca, Boehringer Ingelheim, Genentech, Inc.; Meda Pharmaceuticals Inc.; Merck & Co., Inc, Novartis |
Jonathan Corren, MD | Consultant/Advisor: Genentech, Inc: Grant/Research Support: Genentech, Inc.; MedImmune; Sanofi- Aventis U.S. LLC.; Teva Pharmaceuticals Industries Ltd. Speaker's Bureau: Genentech, Inc.; MedImmune; Sanofi- Aventis U.S. LLC.; Teva Pharmaceuticals Industries Ltd. |
Non-faculty: Sandy Breslow; Alison Kemp; Timothy Hayes, MD, PhD; Kristen Scollon; Emma Gilmartin; Nicole Brestowski and Bernard M. Abrams, MD hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Financial Support
This activity has been supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Provider Information
Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.
CME Credit (Physician)
The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, AcademicCME, and Boehringer Ingelheim Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Available Credit
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician